Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ESC
Virtual
2021
Symposium
Date and time:
28.08.2021 at 11:30 - 12:00 CEST
Type:
Corporate Event
Speakers:
Erin Bohula; Mikhail Kosiborod;
Congress:
European Society of Cardiology (ESC)
This Novo Nordisk symposium at ESC Congress 2021 will feature speakers Dr. Erin Bohula and Dr. Mikhail Kosiborod. This session aims to discuss the different clinical guidelines for GLP-1RAs while explaining the gaps that exist between these guidelines. This session will be followed by a discussion on the practical applications of GLP-1RAs in patients with T2D and ASCVD. Attendees will be given the opportunity to ask questions to the speakers during a live panel discussion.

How do guideline recommendations on GLP-1RA use affect clinical practice?

Practical applications of GLP-1RAs

Live panel discussion

Erin Bohula - Speaker

Erin Bohula

Brigham and Women’s Hospital & Harvard Medical School, Boston, USA


Erin Bohula is an Associate Physician in Cardiovascular Medicine at Brigham and Women’s Hospital, Boston, MA, USA, an Investigator at the Thromboloysis in Myocardial Infarction Clinical Trials (TIMI) Study Group and an Assistant Professor at Harvard Medical School. Dr Bohula earned her DPhil in Molecular Biology from University of Oxford, Oxford, UK on a Rhodes Scholarship and her medical degree from Harvard Medical School, Boston, MA. Following training at the Brigham and Women’s Hospital, she received board certification in internal medicine, cardiology, and critical care medicine.

 

In her role as a TIMI Study Group Investigator, Dr Bohula studies pharmacologic interventions for cardiometabolic diseases, such as hyperlipidaemia, obesity and atherosclerotic cardiovascular disease. As a cardiac intensivist and researcher, she is interested in innovative therapies and devices for critically ill cardiovascular patients and was involved in creating the Critical Care Cardiology Trials Network, a North American research collaborative of cardiology critical care units (CICU). She was the recipient of the Eugene Braunwald Cardiovascular Medicine Physician Scientist Scholar Award in 2018 and the W. Proctor Harvey MD Young Teacher Award from the ACC in 2017.  


Read full bio
Mikhail Kosiborod - Speaker

Mikhail Kosiborod

Saint Luke’s Mid America Heart Institute, Kansas, USA


Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. Dr. Kosiborod received training in clinical research, epidemiology, and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.

 

Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. Dr. Kosiborod has authored and co-authored over 250 peer-reviewed publications, including scientific statements and position documents. Dr. Kosiborod is involved in the leadership of multiple clinical trials and multi-center registries and is currently the principal investigator of several investigator-initiated, multicenter trials in diabetes and cardiovascular disease.


Read full bio

Related